Related Experiment Video
Updated: Dec 31, 2025

Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
Age Distribution, Comorbidities and Risk Factors for Thrombosis in Prader-Willi Syndrome
Merlin G Butler1, Aderonke Oyetunji1,2, Ann M Manzardo1
1Departments of Psychiatry & Behavioral Sciences and Pediatrics, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Insights
Prader-Willi syndrome (PWS) patients, particularly those with commercial insurance, face a significantly higher risk of developing blood clots like pulmonary embolism and deep vein thrombosis compared to obese individuals without PWS. Age and gender also influence this risk.
Area of Science:
- Genetics and rare diseases
- Cardiovascular health
- Medical informatics
Background:
- Prader-Willi syndrome (PWS) is a genetic imprinting disorder affecting the 15q11.2-q13 chromosome region.
- Obesity-related complications pose a significant mortality risk in PWS, though survival is improving.
- Thrombotic events, including venous thromboembolism (VTE), are uncommon but documented comorbidities in PWS.
Purpose of the Study:
- To investigate the risk of thrombotic events (pulmonary embolism and deep vein thrombosis) in individuals with Prader-Willi syndrome.
- To compare the incidence of VTE in PWS patients with obese controls across different insurance types and age groups.
- To identify risk factors, including age and gender, associated with VTE in the PWS population.
Main Methods:
- Retrospective analysis of national health claims data for 3136 PWS patients and 3945 obese controls.
- Diagnosis confirmation using International Classification of Diseases (ICD)-9 codes.
- Unadjusted and adjusted frequency analyses, odds ratios, and regression analysis to assess risk factors and comorbidities.
Main Results:
- Commercially insured PWS individuals were 2.55 times more likely to experience PE or DVT than obese controls (p=0.013).
- Medicaid-insured PWS individuals showed no significant difference in PE or DVT risk compared to obese controls (p=0.60).
- Age and gender were significant predictors of VTE, independent of insurance type, with increased thrombotic events observed across all PWS age cohorts.
Conclusions:
- PWS patients, especially those commercially insured, exhibit an elevated risk for thrombotic events like PE and DVT.
- Insurance status, age, and gender are critical factors influencing VTE risk in individuals with PWS.
- Further research into the specific mechanisms driving increased thrombotic risk in PWS is warranted.
Abstract:
: Prader-Willi syndrome (PWS) is an imprinting disorder caused by lack of expression of the paternally inherited 15q11.2-q13 chromosome region. The risk of death from obesity-related complications can worsen with age, but survival trends are improving. Comorbidities and their complications such as thrombosis or blood clots and venous thromboembolism (VTE) are uncommon but reported in PWS. Two phases of analyses were conducted in our study: unadjusted and adjusted frequency with odds ratios and a regression analysis of risk factors. Individuals with PWS or non-PWS controls with exogenous obesity were identified by specific International Classification of Diseases (ICD)-9 diagnostic codes reported on more than one occasion to confirm the diagnosis of PWS or exogenous obesity in available national health claims insurance datasets. The overall average age or average age per age interval (0-17yr, 18-64yr, and 65yr+) and gender distribution in each population were similar in 3136 patients with PWS and 3945 non-PWS controls for comparison purposes, with exogenous obesity identified from two insurance health claims dataset sources (i.e., commercial and Medicare advantage or Medicaid). For example, 65.1% of the 3136 patients with PWS were less than 18 years old (subadults), 33.2% were 18-64 years old (adults), and 1.7% were 65 years or older. After adjusting for comorbidities that were identified with diagnostic codes, we found that commercially insured PWS individuals across all age cohorts were 2.55 times more likely to experience pulmonary embolism (PE) or deep vein thrombosis (DVT) than for obese controls (p-value: 0.013; confidence interval (CI) :1.22-5.32). Medi caid-insured individuals across all age cohorts with PWS were 0.85 times more likely to experience PE or DVT than obese controls (p-value: 0.60; CI: 0.46-1.56), with no indicated age difference. Age and gender were statistically significant predictors of VTEs, and they were independent of insurance coverage. There was an increase in occurrence of thrombotic events across all age cohorts within the PWS patient population when compared with their obese counterparts, regardless of insurance type.
More Related Videos
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
13:08Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis I: Introduction
Venous Thrombosis III: Interprofessional Care
Peripheral Artery Disease I: Introduction
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation